Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents

NCT ID: NCT04966299

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-18

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Childhood and adolescence are crucial periods for prevention of obesity, as obese children are five times more likely to be obese at adulthood than lean children. To this purpose, sugar consumption should be reduced. The sugar alcohol erythritol is increasingly popular as sugar substitute in the food industry and is also recommended to diabetic patients. The substance is freely available. Recent acute studies show that erythritol has a positive influence on satiation and gastric emptying without affecting insulin and plasma glucose. In this trial, the investigators aim to assess the effect of a chronic intake of erythritol versus sucrose on insulin resistance in healthy adolescents.

EryClot-Pilot:

Erythritol is also produced by the human body and possibly elevated erythritol levels in the blood are an indication of an increased risk of cardiovascular disease, obesity or diabetes in the future.

In a recently published study, a possible effect of erythritol on blood clotting function was described. In this in vitro experiment, increased blood clotting was observed when erythritol was added to clotting cells (platelets) in the test tube. Studies in humans on blood coagulation after administration of erythritol are missing so far.

With a pilot study, the investigators study whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood coagulation function after administration of erythritol will be investigated.

These preliminary tests serve to clarify the data situation so that further studies can be based on them.

The preliminary results of the EryClot\_Pilot study indicate that there appears to be no measurable effect of erythritol on thrombocyte aggregation. This implicates that there is a discrepancy between our results and the results reported in a recent published study. This is why we need to assess the effects of erythritol administration on more parameters of blood coagulation as well as in more subjects.

Due to a study published in June 2024, there appears the need to investigate the effects of xylitol on blood clotting function as well.

EryClot in vitro:

In addition to the human EryClot study, we will conduct in vitro experiments (aggregometry assay after addition of erythritol or xylitol in human platelet rich plasma).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial aims to assess the effects of the daily intake of an erythritol-sweetened beverage over 5 weeks on insulin resistance, glucose tolerance and metabolism as well as on gut microbiota. Moreover, this study will also assess the effect of the above-mentioned intervention on food intake, body composition and gastrointestinal tolerance in this population.

EryClot-Pilot:

The aim of this pilot study is to investigate whether erythritol is detectable in the blood after administration of glucose and fructose. Furthermore, the erythritol level in the blood and a possible effect on the blood clotting function after administration of erythritol will be investigated.

EryClot:

The aim of this study is to investigate the erythritol level in blood after administration of erythritol and a possible effect on blood clotting function. Additionally, a possible effect of xylitol on blood clotting function will be investigated.

EryClot in vitro:

The aim of this study is to investigate the platelet responsiveness in vitro in human plasma after addition of erythritol and xylitol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Glucose Tolerance Body Composition Gastrointestinal Tolerance Thrombocyte Aggregation Blood p-Selectin Blood Erythritol Blood Xylitol

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

EryClot-Pilot:

This trial is a randomized, double-blind, crossover trial. The project set-up is single-center, national. In total, 3 volunteers will be enrolled. There will be 3 study arms.

EryClot This trial is a randomized single-blind, crossover trial. The project setup is single-center national. In total 10 volunteers will be enrolled. There will be 3 study arms.

EryClot in vitro This trial is an in vitro trial using human blood samples. The project setup is single-center national. In total blood samples from 12 volunteers will be collected.
Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sucrose

15 participants receive 25g sucrose per day during 5 weeks

Group Type ACTIVE_COMPARATOR

Sucrose

Intervention Type DIETARY_SUPPLEMENT

Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks

Erythritol

15 participants receive 36g eryhtritol per day during 5 weeks

Group Type EXPERIMENTAL

Eryhtritol

Intervention Type DIETARY_SUPPLEMENT

Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks

EryClot-Pilot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot-Pilot Erythritol

3 participants receive 50g erythritol dissolved in 300mL water once during the visit

Group Type EXPERIMENTAL

Eryhtritol

Intervention Type DIETARY_SUPPLEMENT

Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks

EryClot-Pilot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot-Pilot Glucose

3 participants receive 75g glucose dissolved in 300mL water once during the visit

Group Type ACTIVE_COMPARATOR

Glucose

Intervention Type DIETARY_SUPPLEMENT

Glucose 75g dissolved in 300mL water administered once per visit

EryClot-Pilot Fructose

3 participants receive 25g fructose dissolved in 300mL water once during the visit

Group Type ACTIVE_COMPARATOR

Fructose

Intervention Type DIETARY_SUPPLEMENT

Fructose 25g dissolved in 300mL water administered once per visit

EryClot Erythritol

10 participants receive 50g erythritol dissolved in 300mL water once during the visit

Group Type EXPERIMENTAL

Eryhtritol

Intervention Type DIETARY_SUPPLEMENT

Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks

EryClot-Pilot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot Xylitol

10 participants receive 33.5g xylitol dissolved in 300mL water once during the visit

Group Type EXPERIMENTAL

Xylitol

Intervention Type DIETARY_SUPPLEMENT

Xylitol 33.5g dissolved in 300mL water administered once per visit

EryClot Water

10 participants receive 300mL water once during the visit

Group Type PLACEBO_COMPARATOR

Water

Intervention Type DIETARY_SUPPLEMENT

300mL water administered once per visit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eryhtritol

Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks

EryClot-Pilot:

Erythritol 50g dissolved in 300mL water administered once per visit

EryClot:

Erythritol 50g dissolved in 300mL water administered once per visit

Intervention Type DIETARY_SUPPLEMENT

Sucrose

Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks

Intervention Type DIETARY_SUPPLEMENT

Glucose

Glucose 75g dissolved in 300mL water administered once per visit

Intervention Type DIETARY_SUPPLEMENT

Fructose

Fructose 25g dissolved in 300mL water administered once per visit

Intervention Type DIETARY_SUPPLEMENT

Xylitol

Xylitol 33.5g dissolved in 300mL water administered once per visit

Intervention Type DIETARY_SUPPLEMENT

Water

300mL water administered once per visit

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

E968-Erythritol E967-Xylitol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adolescents
* Aged 14-18 years
* Normal weight (BMI between 15th and 85th percentile for age and gender)
* Minimum weight of 45kg
* Regular sugar consumption \>25g/d


* Healthy participants 18-55 years upon inclusion
* Normal weight (BMI between 19.0-24.9 kg/m2)
* Informed consent signed by participant


* Healthy participants 18-55 years upon inclusion
* Normal weight (BMI between 19.0-24.9 kg/m2)
* Informed consent signed by participant,


* Healthy participants 18-55 years upon inclusion
* BMI \< 30 kg/m2
* Informed consent signed by participant

Exclusion Criteria

* Severe acute or chronic diseases
* Pregnancy
* Regular intake of prebiotics
* Regular intake of probiotics
* Regular intake of pro-/prebiotic foods
* Antibiotics cure within 3 months preceding the present study
* Substance abuse
* Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol
* Fructose-intolerance
* Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction, etc.)

EryClot-Pilot:

3 participants


* Severe acute or chronic diseases
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening
* Substance abuse, smoking
* Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol
* Fructose-intolerance

EryClot:


* Severe acute or chronic diseases
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening
* Substance abuse, smoking
* Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German)
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol or xylitol
* Pre-existing impairment of blood coagulation/thrombocyte function (e.g., hereditary, regular intake of anti-coagulant agents (e.g., NSAIDs, heparin, warfarin, etc.))

EryClot in vitro


* Severe acute or chronic diseases
* Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded.
* Substance abuse, smoking
* Inability to follow procedures due to psychological disorders
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
* Pre-existing regular consumption (\>1/week) of erythritol or xylitol
* Pre-existing impairment of blood coagulation/thrombocyte function (e.g., hereditary, regular intake of anti-coagulant agents (e.g., NSAIDs, heparin, warfarin, etc.))
Minimum Eligible Age

14 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bettina K. Wölnerhanssen, PD. MD

Role: PRINCIPAL_INVESTIGATOR

St. Clara Research Ltd.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Claraspital

Basel, Canton of Basel-City, Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bettina K. Wölnerhanssen, PD. MD

Role: CONTACT

+ 41 61 685 86 32

Anne Christin Meyer-Gerspach, PD. PhD

Role: CONTACT

+41 61685 86 44

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bettina K. Wölnerhanssen, PD. MD

Role: primary

+41 61 685 86 32

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EryAdo

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Exogenous Ketones and Glucose Tolerance
NCT03461068 COMPLETED PHASE1